A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

  • STATUS
    Recruiting
  • End date
    Aug 31, 2022
  • participants needed
    205
  • sponsor
    AbbVie
Updated on 2 June 2021
Investigator
AbbVie_Call Center
Primary Contact
Ingalls Memorial Hosp /ID# 171221 (3.0 mi away) Contact
+24 other location
cancer
myeloid leukemia
hematologic malignancy
lymphoma
hodgkin's disease
measurable disease
leukemia
bone marrow procedure
KRAS
bevacizumab
primary cancer
solid tumour
solid tumor
solid neoplasm

Summary

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignancies.

Details
Condition Hematologic Malignancy, Blood disorder, Cancer, Cancer/Tumors, Solid Tumors, Advanced Solid Tumors, Ewing's Family Tumors, Cancer (Pediatric), Advanced Solid Tumors Cancer, Blood Cancer, Neoplasms, Hematologic Cancer, Hematological Disorders, Hematologic Neoplasms, primary cancer, primary malignant neoplasm, malignancy, cancers, malignancies, malignant tumor, malignant tumors, hematological malignancy, hematologic malignancies, hematological tumor, haematological malignancy, hematological malignancies
Treatment Gemcitabine, bevacizumab, Nab-paclitaxel, FOLFIRI, venetoclax, ABBV-621
Clinical Study IdentifierNCT03082209
SponsorAbbVie
Last Modified on2 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Must have a diagnosis of a solid tumor (except primary brain tumors), acute myeloid leukemia (AML), or non-Hodgkin lymphoma (NHL); NHL may be of any subtype for Dose Escalation but is limited to diffuse large B-cell lymphoma (DLBCL) for those enrolled to the cohort evaluating the combination of ABBV-621 and venetoclax. Participants in the Dose Optimization solid tumor cohorts must have either colorectal cancer with documented KRAS mutations (as determined by local testing), or pancreatic cancer (irrespective of mutational status). Participants in the chemotherapy combination cohorts must have metastatic or advanced unresectable colorectal cancer with documented RAS mutations (as determined by local testing)
Participant in dose escalation or dose optimization cohort must have received at least one prior systemic therapy, and must have relapsed or progressed after, or failed to respond to any/all available effective therapy or therapies
Participant in chemotherapy cohorts with CRC must have progressed after or failed to respond to initial systemic therapy
Must have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST] 1.1 for those with solid tumors; by Lugano classification for those with NHL), except those with AML, who must have histologically confirmed relapsed or refractory disease
Must agree to provide the following samples for biomarker analysis
All participants: archived tumor tissue (if available)
Participants in Dose Optimization (excluding AML): pre- and on-treatment fresh tissue biopsies. (Note: fresh tissue biopsies will be optional for participants with solid tumor or NHL in Dose Escalation and will be collected only if consent is provided)
All participants with AML: pre- and on-treatment bone marrow aspirates (BMA)
Participants in chemotherapy combination cohorts: participants must provide a fresh biopsy if an archival biopsy is not available
Participant in chemotherapy cohorts with CRC must have confirmed RAS mutation
Must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 - 2. Participants in chemotherapy combination cohorts must have ECOG Performance Score of 0
\
Must have adequate hematologic, renal and hepatic function

Exclusion Criteria

Participants with history of brain metastases who have not shown clinical and radiographic stable disease for at least 28 days after definitive therapy. In addition, any AML participant identified through cerebrospinal fluid (CSF) analysis, as having active central nervous system (CNS) disease, will be excluded
Presence of primary hepatobiliary malignancy, including cholangiocarcinoma or hepatocellular carcinoma, gallbladder carcinoma, cancer of ampulla of Vater
Receipt of any systemic anti-cancer agent, including investigational anti-cancer products, within 21 days prior to study drug administration or 3 half-lives, whichever is longer
Participant with a history of cirrhosis or other indication of significant possible hepatic dysfunction. Note: Those with non-alcoholic steatohepatitis (NASH) should be discussed with the AbbVie TA MD before enrollment
Participant with a positive diagnosis of hepatitis A, B, or C
Dose Optimization combination cohorts only: Prior receipt, at any time, of a BCL-2 inhibitor
Dose Optimization combination cohorts only: Participant has received strong or moderate CYP3A inhibitors or inducers within 7 days prior to the initiation of study treatment
Dose Optimization combination cohorts only: Participant has malabsorption syndrome or other condition that precludes enteral route of administration
Dose Optimization combination cohorts only: Participant has promyelocytic leukemia (M3)
CRC chemotherapy cohort only: Participant with minor surgical procedures, such as fine needle aspirations or core biopsies, within 7 days prior to first dose of study drug are excluded
Participants in CRC chemotherapy combination cohort only: cardiomyopathy, coronary/peripheral artery bypass graft, aneurysm or aneurysm repair, angioplasty, pulmonary hypertension, cerebrovascular accident or transient ischemic attack, within 1 year of first dose of study drug
Chemotherapy combination CRC participants only: Prior receipt of an irinotecan-based chemotherapy
Chemotherapy combination CRC participants only: Disease progression within 3-months of initiating first-line therapy
Chemotherapy combination CRC participants only: history of Gilbert's syndrome or UG1T1A1 genotypes
Chemotherapy combination with bevacizumab participants only: clinically significant conditions that may place the participant at higher risk with anti-angiogenic therapy
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note